Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
Status:
Completed
Trial end date:
2019-04-24
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if adding Zevalin (ibritumomab tiuxetan)
to low-intensity chemotherapy (the combination of rituximab, bendamustine, and fludarabine),
followed by an allogeneic stem cell transplant, can help to control lymphoma. The safety of
this combination will also be studied.
Two (2) forms of ibritumomab tiuxetan will be used in this study. 90Y-ibritumomab tiuxetan is
designed to attach to lymphoma cells and destroy the cells using a radioactive particle that
is attached to it. 111In-ibritumomab tiuxetan is like 90Y- ibritumomab tiuxetan, but the
radioactive particle that is attached to it does not kill lymphoma cells. The radioactive
particle makes the drug able to be seen inside your body. It is being used in this study to
predict how fast the study drug will travel in the body and how long the drug stays in the
body.
Rituximab is designed to attach to lymphoma cells, which may cause them to die.
Bendamustine is designed to damage and destroy the DNA (genetic material) of cancer cells.
Fludarabine is designed to make cancer cells less able to repair damaged DNA. This may
increase the likelihood of the cells dying.